Aminopeptidase secreted by Chromobacterium sp. Panama inhibits dengue virus infection by degrading the E protein
Open Access
- 25 April 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 12 (4) , e0006443
Abstract
Dengue virus (DENV) is the most prevalent and burdensome arbovirus transmitted by Aedes mosquitoes, against which there is only a limited licensed vaccine and no approved drug treatment. A Chromobacterium species, C. sp. Panama, isolated from the midgut of A. aegypti is able to inhibit DENV replication within the mosquito and in vitro. Here we show that C. sp. Panama mediates its anti-DENV activity through secreted factors that are proteinous in nature. The inhibitory effect occurs prior to virus attachment to cells, and is attributed to a factor that destabilizes the virion by promoting the degradation of the viral envelope protein. Bioassay-guided fractionation, coupled with mass spectrometry, allowed for the identification of a C. sp. Panama-secreted neutral protease and an aminopeptidase that are co-expressed and appear to act synergistically to degrade the viral envelope (E) protein and thus prevent viral attachment and subsequent infection of cells. This is the first study characterizing the anti-DENV activity of a common soil and mosquito-associated bacterium, thereby contributing towards understanding how such bacteria may limit disease transmission, and providing new tools for dengue prevention and therapeutics. The global burden of dengue cannot be overstated, and lack of effective control measures, besides avoiding contact with the mosquito vector, creates an urgent need to develop new strategies to control the disease. Here we elucidate the mechanism by which a natural soil bacterium inhibits DENV infection. Chromobacterium sp. Panama secretes a protease that is able to undermine the integrity of the viral particles, preventing their attachment and thus infection of host cells. This study contributes towards understanding how natural bacteria of the vector gut may limit disease transmission, and provides new candidate tools for the development of dengue transmission-blocking and therapeutic agents.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (RO1AI101431)
- Boehringer Ingelheim
This publication has 44 references indexed in Scilit:
- Sulfated Escherichia coli K5 Polysaccharide Derivatives Inhibit Dengue Virus Infection of Human Microvascular Endothelial Cells by Interacting with the Viral Envelope Protein E Domain IIIPLOS ONE, 2013
- Bispidine-Amino Acid Conjugates Act as a Novel Scaffold for the Design of Antivirals That Block Japanese Encephalitis Virus ReplicationPLOS Neglected Tropical Diseases, 2013
- Dengue Virus Infection of the Aedes aegypti Salivary Gland and Chemosensory Apparatus Induces Genes that Modulate Infection and Blood-Feeding BehaviorPLOS Pathogens, 2012
- Proteases as therapeuticsBiochemical Journal, 2011
- Flavivirus Cell Entry and Membrane FusionViruses, 2011
- Transgenesis and paratransgenesis to control insect-borne diseases: Current status and future challengesParasitology International, 2010
- Engineering botulinum neurotoxin to extend therapeutic interventionProceedings of the National Academy of Sciences, 2009
- Heterologous expression and purification of Vibrio proteolyticus (Aeromonas proteolytica) aminopeptidase: A rapid protocolProtein Expression and Purification, 2009
- Protocol for Dengue Infections in Mosquitoes (A. aegypti) and Infection Phenotype DeterminationJournal of Visualized Experiments, 2007
- A Secreted Aminopeptidase of Pseudomonas aeruginosaJournal of Biological Chemistry, 2001